Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kell, P.
Right arrow Articles by Ralph, D.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Apomorphine SL in the treatment of erectile dysfunction

Philip Kell

The Archway Sexual Health Clinic, Whittington Hospital, Highgate Hill, London, N19 5NF, UK, Pdkell{at}hotmail.com

John Dean

The Archway Sexual Health Clinic, Whittington Hospital, Highgate Hill, London, N19 5NF, UK

David Ralph

The Archway Sexual Health Clinic, Whittington Hospital, Highgate Hill, London, N19 5NF, UK

Men with erectile dysfunction (ED) have a high incidence of comorbid cardiovascular disease and diabetes. Additionally, some drugs used to treat cardiovascular disease have been implicated as contributors to ED. Sublingual (SL) apomorphine (Uprima®), a compound with D2-like dopamine receptor agonist effects, has a rapid onset of action, resulting in erectile response within 10 minutes of dosing in some patients (median onset of effect is 18—19 minutes). Apomorphine SL improves erectile function in men with mild-to-moderate ED and is well tolerated in patients with diabetes and/or cardiovascular disease.

Key Words: apomorphine SL • cardiovascular disease • diabetes • erectile dysfunction.

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 4, 296-300 (2002)
DOI: 10.1177/14746514020020041101
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?